Keywords
Exploration
Accueil
Racine
Exploration
Accueil
Racine

Movement Disorders (revue) - Exploration (Accueil)

Index « Keywords » - entrée « MAO B inhibitor »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
MAO < MAO B inhibitor < MAO inhibitor  Facettes :

List of bibliographic references indexed by MAO B inhibitor

Number of relevant bibliographic references: 11.
Ident.Authors (with country if any)Title
003455 (2006) J. Antonelle Demarcaida [États-Unis] ; Steven R. Schwid [États-Unis] ; William B. White [États-Unis] ; Karen Blindauer [États-Unis] ; Stanley Fahn [États-Unis] ; Karl Kieburtz [États-Unis] ; Matthew Stern [États-Unis] ; Ira Shoulson [États-Unis]Effects of tyramine administration in Parkinson's disease patients treated with selective MAO‐B inhibitor rasagiline
003A84 (2004) Cheryl H. Waters [États-Unis] ; Kapil D. Sethi [États-Unis] ; Robert A. Hauser [États-Unis] ; Eric Molho [États-Unis] ; John M. Bertoni [États-Unis]Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3‐month, randomized, placebo‐controlled study
003E24 (2004) Susan Hollán [Hongrie] ; Lászl Vécsei [Hongrie] ; Kálmán Magyar [Hongrie]Adverse effects of dopamine potentiation by long‐term treatment with selegiline
004594 (2002) Treatment of depression in idiopathic Parkinson's disease
004606 (2002) MAO-B inhibitors for the treatment of Parkinson's disease
004D56 (1999) Robert B. Innis ; Kenneth L. Marek ; Kim Sheff ; Sami Zoghbi ; Joseph Castronuovo [États-Unis] ; Andrew Feigin [États-Unis] ; John P. SeibylEffect of treatment with L‐dopa/carbidopa or L‐selegiline on striatal dopamine transporter SPECT imaging with [123I]β‐CIT
005093 (1998) Robert A. Hauser [États-Unis] ; Eric Molho [États-Unis] ; Heidi Shale [États-Unis] ; Simon Pedder [États-Unis] ; Ernest E. Dorflinger [États-Unis]A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients
005428 (1997) Nathalie Andreu [France] ; Christine Damase-Michel [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Montastruc [France]A dose‐ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity
005448 (1997) P. Lewitt [États-Unis] ; D. Oakes [États-Unis] ; L. Cui [États-Unis]The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α-tocopherol
005450 (1997) J. P. Larsen [Norvège] ; J. Boas [Danemark]The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability : An interim analysis of a Norwegian-Danish 5-year study
005462 (1997) J. Lyytinen [Finlande] ; S. Kaakkola [Finlande] ; S. Ahtila [Finlande] ; P. Tuomainen [Finlande] ; H. Ter V Inen [Finlande]Simultaneous MAO-B and COMT inhibition in L-dopa-treated patients with Parkinson's disease

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "MAO B inhibitor" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "MAO B inhibitor" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    MAO B inhibitor
}}
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024